Simmons Jeffrey N

CEO Simmons buys 4,971 shares of ELAN at $20.08; stock down -28.6% from 52-week high

CEO and President Jeffrey N Simmons purchased 4,971 shares at $20.08 on 2026-05-15, increasing his holdings to 171,971 shares. The purchase occurs against a backdrop of material price weakness: the stock trades at $19.80, down -28.6% from its 52-week high of $27.72 and down -16.4% over the prior 30 days. Fundamentals show the company generated $1,371,000,000 in quarterly revenue with annual revenue growth of 6.2%, though the company was unprofitable over its most recent full fiscal year. The timing of this insider purchase during a period of elevated price pressure warrants attention, particularly given the stock's cumulative decline across multiple timeframes.

Elanco CEO Simmons buys 22,000 shares for $478.5K; cluster of 3 other insiders also bought in past 14 days.

On 2025-12-11, Simmons Jeffrey N (PRESIDENT, CEO AND DIRECTOR) purchased 22,000 shares of Elanco Animal Health Inc (ELAN) at $21.75, increasing his holdings from 145,000 to 167,000 shares. The transaction occurred amid a cluster of 3 other insider purchases within the past 14 days, suggesting coordinated confidence at current levels. Elanco is trading at $21.70 (near the transaction price), down 7.4% from its 52-week high of $23.43, and has posted a 90-day return of +16.5%. The company faces headwinds: net income is currently negative at $-34.0M on revenue of $1.1B, with minimal annual growth of +0.5% and a stretched P/E of 310.00, reflecting an unprofitable near-term picture.

CEO Simmons purchases 100,000 shares of ELAN at $13.01; holdings triple to 145,000 amid unprofitability

CEO Jeffrey Simmons purchased 100,000 shares (100.0K shares) at $13.01, tripling his holdings from 45,000 shares (45.0K shares) to 145,000 shares (145.0K shares). This substantial open-market accumulation by the top executive occurs while Elanco faces material headwinds: the company posted a net loss of $-50,000,000 ($-50.0M) in its most recent fiscal year and reported negative net income in the latest quarter, with annual revenue growth stalled at +0.1%. The stock has declined 24.4% from its 52-week high of $18.45 and is down 18.2% over the past 90 days, trading at $13.94 today—just $0.93 above the transaction price. A CEO acquiring shares of this magnitude during a period of operating losses and negative momentum warrants investor attention to the company's operational trajectory and management's internal view of recovery prospects.